Anzeige
Mehr »
Dienstag, 16.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40LQ4 | ISIN: US01626L2043 | Ticker-Symbol: 5WK0
Tradegate
15.09.25 | 20:07
7,950 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ALIGOS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ALIGOS THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,5508,05016:16
7,6507,95016:10

Aktuelle News zur ALIGOS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiHealth Canada approves Medison and Ipsen's Bylvay to treat ALGS2
ALIGOS THERAPEUTICS Aktie jetzt für 0€ handeln
03.09.Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting3
20.08.Aligos Therapeutics appoints Ramón Polo as head of global regulatory9
20.08.Aligos Therapeutics beruft Ramón Polo zum Leiter der globalen Zulassungsangelegenheiten6
20.08.Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Ramón Polo as Senior Vice President, Head of Global Regulatory Affairs107SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class...
► Artikel lesen
18.08.Aligos Therapeutics stock gets Buy rating from H.C. Wainwright on HBV drug potential6
18.08.Aligos Therapeutics: H.C. Wainwright startet Coverage mit "Buy"-Rating wegen Potenzial bei Hepatitis-B-Wirkstoff6
15.08.Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)130SOUTH SAN FRANCISCO, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos", "Company"), a clinical stage biopharmaceutical company focused on improving patient...
► Artikel lesen
13.08.Aligos begins dosing in phase 2 HBV drug study2
13.08.Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection167SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biopharmaceutical company focused on improving patient outcomes...
► Artikel lesen
06.08.Aligos Therapeutics GAAP EPS of -$1.53 beats by $0.838
06.08.Aligos Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans16
06.08.Aligos Therapeutics, Inc. - 10-Q, Quarterly Report3
06.08.Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results133SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos"), a clinical stage biotechnology company focused on improving patient outcomes through...
► Artikel lesen
06.08.Aligos Therapeutics, Inc. - 8-K, Current Report1
30.07.Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 20256
11.07.Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)145SOUTH SAN FRANCISCO, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos", "Company"), a clinical stage biopharmaceutical company focused on improving patient...
► Artikel lesen
18.06.Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)3
13.06.Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)217SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, "Aligos", "Company"), a clinical stage biopharmaceutical company focused on improving patient...
► Artikel lesen
20.05.Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal12
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2